Research ExplorerPublicationsAllogeneic hematopoietic cell transplantation in patients wi...

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

Standard

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. / Shimoni, Avichai; Robin, Marie; Iacobelli, Simona; Beelen, Dietrich; Mufti, Ghulam J; Ciceri, Fabio; Bethge, Wolfgang; Volin, Liisa; Blaise, Didier; Ganser, Arnold; Luft, Thomas; Chevallier, Patrice; Schwerdtfeger, Rainer; Koster, Linda; de Witte, Theo; Kröger, Nicolaus; Nagler, Arnon; Yakoub-Agha, Ibrahim.

In: BRIT J HAEMATOL, Vol. 195, No. 3, 11.2021, p. 417-428.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Shimoni, A, Robin, M, Iacobelli, S, Beelen, D, Mufti, GJ, Ciceri, F, Bethge, W, Volin, L, Blaise, D, Ganser, A, Luft, T, Chevallier, P, Schwerdtfeger, R, Koster, L, de Witte, T, Kröger, N, Nagler, A & Yakoub-Agha, I 2021, 'Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT', BRIT J HAEMATOL, vol. 195, no. 3, pp. 417-428. https://doi.org/10.1111/bjh.17817

APA

Shimoni, A., Robin, M., Iacobelli, S., Beelen, D., Mufti, G. J., Ciceri, F., Bethge, W., Volin, L., Blaise, D., Ganser, A., Luft, T., Chevallier, P., Schwerdtfeger, R., Koster, L., de Witte, T., Kröger, N., Nagler, A., & Yakoub-Agha, I. (2021). Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. BRIT J HAEMATOL, 195(3), 417-428. https://doi.org/10.1111/bjh.17817

Vancouver

Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. BRIT J HAEMATOL. 2021 Nov;195(3):417-428. https://doi.org/10.1111/bjh.17817

Bibtex

@article{5819ab4b9a60413497a5ff1c32a3ead9,
title = "Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT",
abstract = "Allogeneic haematopoietic-cell transplantation (allo-HCT) is a potentially curative therapy for high-risk myelodysplastic syndrome (MDS). Reduced-intensity conditioning (RIC) is usually associated with lower non-relapse mortality (NRM), higher relapse rate and similar overall-survival (OS) as myeloablative-conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced-toxicity regimen with intense anti-leukaemia activity and a favourable toxicity profile. We investigated post-transplant outcomes in 1722 MDS patients following allo-HCT with FT (n = 367), RIC (n = 687) or MAC (n = 668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0·001) but other disease characteristics were similar. The median follow-up was 64 months (1-171). Five-year relapse rates were 25% (21-30), 38% (34-42) and 25% (22-29), after FT, RIC and MAC, respectively, (P < 0·001). NRM was 30% (25-35), 27% (23-30) and 34% (31-38, P = 0·008), respectively. Five-year OS was 50% (44-55), 43% (38-47), and 43% (39-47), respectively (P = 0·03). In multivariate analysis, FT was associated with a lower risk of relapse (HR 0·55, P < 0·001) and better OS (HR 0·72, P = 0·01). MAC was associated with higher NRM (HR 1·44, P = 0·001). In conclusion, FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved OS. FT may be the preferred regimen for allo-HCT in MDS.",
author = "Avichai Shimoni and Marie Robin and Simona Iacobelli and Dietrich Beelen and Mufti, {Ghulam J} and Fabio Ciceri and Wolfgang Bethge and Liisa Volin and Didier Blaise and Arnold Ganser and Thomas Luft and Patrice Chevallier and Rainer Schwerdtfeger and Linda Koster and {de Witte}, Theo and Nicolaus Kr{\"o}ger and Arnon Nagler and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2021 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2021",
month = nov,
doi = "10.1111/bjh.17817",
language = "English",
volume = "195",
pages = "417--428",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

AU - Shimoni, Avichai

AU - Robin, Marie

AU - Iacobelli, Simona

AU - Beelen, Dietrich

AU - Mufti, Ghulam J

AU - Ciceri, Fabio

AU - Bethge, Wolfgang

AU - Volin, Liisa

AU - Blaise, Didier

AU - Ganser, Arnold

AU - Luft, Thomas

AU - Chevallier, Patrice

AU - Schwerdtfeger, Rainer

AU - Koster, Linda

AU - de Witte, Theo

AU - Kröger, Nicolaus

AU - Nagler, Arnon

AU - Yakoub-Agha, Ibrahim

N1 - © 2021 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2021/11

Y1 - 2021/11

N2 - Allogeneic haematopoietic-cell transplantation (allo-HCT) is a potentially curative therapy for high-risk myelodysplastic syndrome (MDS). Reduced-intensity conditioning (RIC) is usually associated with lower non-relapse mortality (NRM), higher relapse rate and similar overall-survival (OS) as myeloablative-conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced-toxicity regimen with intense anti-leukaemia activity and a favourable toxicity profile. We investigated post-transplant outcomes in 1722 MDS patients following allo-HCT with FT (n = 367), RIC (n = 687) or MAC (n = 668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0·001) but other disease characteristics were similar. The median follow-up was 64 months (1-171). Five-year relapse rates were 25% (21-30), 38% (34-42) and 25% (22-29), after FT, RIC and MAC, respectively, (P < 0·001). NRM was 30% (25-35), 27% (23-30) and 34% (31-38, P = 0·008), respectively. Five-year OS was 50% (44-55), 43% (38-47), and 43% (39-47), respectively (P = 0·03). In multivariate analysis, FT was associated with a lower risk of relapse (HR 0·55, P < 0·001) and better OS (HR 0·72, P = 0·01). MAC was associated with higher NRM (HR 1·44, P = 0·001). In conclusion, FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved OS. FT may be the preferred regimen for allo-HCT in MDS.

AB - Allogeneic haematopoietic-cell transplantation (allo-HCT) is a potentially curative therapy for high-risk myelodysplastic syndrome (MDS). Reduced-intensity conditioning (RIC) is usually associated with lower non-relapse mortality (NRM), higher relapse rate and similar overall-survival (OS) as myeloablative-conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced-toxicity regimen with intense anti-leukaemia activity and a favourable toxicity profile. We investigated post-transplant outcomes in 1722 MDS patients following allo-HCT with FT (n = 367), RIC (n = 687) or MAC (n = 668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0·001) but other disease characteristics were similar. The median follow-up was 64 months (1-171). Five-year relapse rates were 25% (21-30), 38% (34-42) and 25% (22-29), after FT, RIC and MAC, respectively, (P < 0·001). NRM was 30% (25-35), 27% (23-30) and 34% (31-38, P = 0·008), respectively. Five-year OS was 50% (44-55), 43% (38-47), and 43% (39-47), respectively (P = 0·03). In multivariate analysis, FT was associated with a lower risk of relapse (HR 0·55, P < 0·001) and better OS (HR 0·72, P = 0·01). MAC was associated with higher NRM (HR 1·44, P = 0·001). In conclusion, FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved OS. FT may be the preferred regimen for allo-HCT in MDS.

U2 - 10.1111/bjh.17817

DO - 10.1111/bjh.17817

M3 - SCORING: Journal article

C2 - 34514596

VL - 195

SP - 417

EP - 428

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 3

ER -